Photo by JESHOOTS.com on Pexels.com

Proteostasis Therapeutics Stock Price Skyrockets From Positive FDA Phase 1 Results

Proteostasis Therapeutics Announces Positive Preliminary FDA Phase 1 Results

(By Glenford S Robinson)

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), stock price skyrocketed 300% today, October 18, 2017 on positive Phase 1 study news from the Food and Drug Administration (FDA), which stated that the company’s proprietary doublet PTI-801 and PTI-808 cystic fibrosis research medicines have proven safe at the dosage level administered to research volunteers. The study volunteers consist of 20 to 100 individuals, which includes healthy people and those with the disease.

Proteostasis Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company focused on developing therapies effective against cystic fibrosis (CF), a diseased caused by the dysfunctional processing of protein in the human body.

Armed with over 450 issued patents and a topnotch group of research scientists in technology, pharmaceuticals, and healthcare, PTI is confident that it can support its claim as the Inventor of Digital Medicine. In fact, a positive Phase 1 result of its cystic fibrosis research drug study is a strong indication that the company is capable of supporting such claim, as the undisputed Inventor of Digital Medicine.

The company claimed to be the Inventor of Digital Medicine, simply because it has developed a new category of pharmaceuticals that measures the effectiveness of medication treatment, help physicians in improving clinical outcomes and thus, help patients accomplish health goals.

Proteostasis Therapeutics plans to bring its new digital solution to healthcare providers by coordinating its efforts with leading health systems and pharmaceutical companies which will increase access to better insights, optimized therapies, and reduced costs.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved.

Glenford Robinson

I am a Clinical Lab Scientist, entrepreneur, investor and trader (stocks and Forex). I enjoy writing and publishing articles online.

Check Also

Teva Stock Price Rise as Investors Welcomed Promising Sign of Progress

TEVA Stock on the Rise Again and Investors are Witnessing Progress

Biotechnology Juggernaut Veracyte (VCYT) Up 27% a Day after Beating Estimates

Veracyte, a Biotech Stock on the Rise.

Grim Outlook for EUR-USD Currency Pair

The EURO is sinking fast.

Canopy Growth Corp Stock (CGC) Current Outlook

CGC stock price is falling like a brick; when will this price decline end?

FDA Approves Marketing of Woman’s Menopausal Status PicoAMH Test

FDA Approvals and Releases

Bitcoin Now Legal in China as Property But not Legal Tender

China did not ban Bitcoin because Bitcoin and other cryptocurrencies are alive and well in China being legally recognized and treated as property...

Canopy Growth Corp (CGC) Technical Analysis for October 26, 2018

Canopy Growth Corp. stock CGC is currently operating in the Red Zone.

%d bloggers like this: